Literature DB >> 10720065

Close correlation between estrogen treatment and renal phosphate reabsorption capacity.

H Uemura1, M Irahara, N Yoneda, T Yasui, K Genjida, K I Miyamoto, T Aono, E Takeda.   

Abstract

To determine the influence of estrogen on the activity of renal proximal tubular reabsorption of inorganic phosphate (Pi) in women, we examined the changes of the renal threshold phosphate concentration (also denoted as TmP/GFR), as well as the changes in the concentrations of mineral components in the circulation in two groups of women--one receiving hormone replacement therapy (HRT) and one receiving gonadotropin-releasing hormone agonists (GnRH-a) therapy. We also examined the changes in the concentrations of serum PTH in the GnRH-a group. The patients in the HRT group were continuously treated with 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate per day. The patients in the GnRH-a group were treated with a monthly injection of 3.75 mg leuprolide acetate depot for 6 months. The values of TmP/GFR decreased in all of the patients who received HRT. The mean percentage change in TmP/GFR was -14.5% (range, -24.3% to -9.6%). In contrast, in all of the patients treated with GnRH-a, the values of TmP/GFR increased after 6 months of treatment (the mean percentage change was 28.5%; range, 18.2-78.3%) and returned to the preadministration level at 12 weeks after stopping therapy. In these patients, both the values of TmP/GFR and the concentrations of serum Pi correlated significantly with circulating estradiol levels (r = -0.767, P < 0.01 and r = -0.797, P < 0.01, respectively), but the concentrations of serum corrected calcium did not correlate. Moreover, in the same patients, the levels of serum intact PTH decreased significantly (P < 0.05) after 6 months of treatment, but at 12 weeks after stopping therapy the trends of these levels varied among individual patients. These results suggest that estrogen could act directly to suppress sodium-dependent Pi reabsorption in the renal proximal tubules.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720065     DOI: 10.1210/jcem.85.3.6456

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

1.  Associations of estradiol and testosterone with serum phosphorus in older men: the Osteoporotic Fractures in Men study.

Authors:  Jerry Meng; Claes Ohlsson; Gail A Laughlin; Michel Chonchol; Christina L Wassel; Osten Ljunggren; Magnus K Karlsson; Dan Mellstrom; Eric S Orwoll; Elizabeth Barrett-Connor; Joachim H Ix
Journal:  Kidney Int       Date:  2010-06-09       Impact factor: 10.612

Review 2.  Physical activity in the prevention and amelioration of osteoporosis in women : interaction of mechanical, hormonal and dietary factors.

Authors:  Katarina T Borer
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

3.  Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study.

Authors:  Joachim H Ix; Michel Chonchol; Gail A Laughlin; Michael G Shlipak; Mary A Whooley
Journal:  Am J Kidney Dis       Date:  2011-08-19       Impact factor: 8.860

4.  Effects of the SERM raloxifene on calcium and phosphate metabolism in healthy middle-aged men.

Authors:  Brigitte Uebelhart; François Herrmann; René Rizzoli
Journal:  Clin Cases Miner Bone Metab       Date:  2009-05

5.  Significance of serum levels of vitamin D and some related minerals in breast cancer patients.

Authors:  Iman A Abdelgawad; Rawya H El-Mously; Magdy M Saber; Ossama A Mansour; Samia A Shouman
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

6.  Klotho/fibroblast growth factor 23- and PTH-independent estrogen receptor-α-mediated direct downregulation of NaPi-IIa by estrogen in the mouse kidney.

Authors:  Rose Webster; Sulaiman Sheriff; Rashma Faroqui; Faraaz Siddiqui; John R Hawse; Hassane Amlal
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18

7.  Indirect regulation of PTH by estrogens may require FGF23.

Authors:  Natalia Carrillo-López; Pablo Román-García; Ana Rodríguez-Rebollar; José Luis Fernández-Martín; Manuel Naves-Díaz; Jorge B Cannata-Andía
Journal:  J Am Soc Nephrol       Date:  2009-07-23       Impact factor: 10.121

8.  Estrogen downregulates the proximal tubule type IIa sodium phosphate cotransporter causing phosphate wasting and hypophosphatemia.

Authors:  S Faroqui; M Levi; M Soleimani; H Amlal
Journal:  Kidney Int       Date:  2008-02-27       Impact factor: 10.612

9.  Fibroblast Growth Factor-23 (FGF-23) Levels Differ Across Populations by Degree of Industrialization.

Authors:  Shennin N Yuen; Holly Kramer; Amy Luke; Pascal Bovet; Jacob Plange-Rhule; Terrence Forrester; Vicki Lambert; Myles Wolf; Pauline Camacho; Regina Harders; Lara Dugas; Richard Cooper; Ramon Durazo-Arvizu
Journal:  J Clin Endocrinol Metab       Date:  2016-03-22       Impact factor: 5.958

10.  Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function.

Authors:  Mengjing Wang; Li You; Haiming Li; Yong Lin; Zhijie Zhang; Chuanming Hao; Jing Chen
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.